|Articles|June 18, 2019

Bioavailability and Development Toolkit

Author(s)Catalent

With global development and manufacturing sites, Catalent combines its formulation and bioavailability enhancement experience, along with delivery technologies to support the launch of more than 100 new products every year.

 

With 85 years’ experience serving the pharmaceutical industry, Catalent is the leading global provider of advanced drug delivery technologies and development solutions for drugs, biologics, gene therapies, and consumer health products.

 

From its three early-phase drug development centres of excellence in Nottingham, UK, Somerset, New Jersey, and San Diego, California, and its network of manufacturing facilities, Catalent offers its partners end-to-end solutions, encompassing early drug product formulation and dose form design, through to clinical supply services, commercial-scale manufacturing and lifecycle management.

 

For early development, these solutions include analytical, pre-formulation and formulation technologies, and Catalent offers the most comprehensive bioavailability enhancing technology toolkit including lipid formulation, spray drying and hot melt extrusion. Its experience sees Catalent support the development and launch of over 100 new products every year.

 

By adapting for each molecule’s unique characteristics and challenges, Catalent uses its experience and a wide range of tools and technologies to create dose forms that benefit patients.

 

Catalent’s multi-award-winning OptiForm® Solution Suite platform can assist in the development of innovative dose forms that can improve a drug’s clinical efficacy and commercial success. OptiForm Solution Suite is fast, flexible and fact-based, combining the broadest selection of enabling technologies to ensure the right decisions are made at each stage of development.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.